广东太安堂药业股份有限公司 《公司章程》修订对照表 广东太安堂药业股份有限公司（以下简称"公司"）于2024年6月19日召开 第六届董事会第十二次会议，审议通过了《关于修订<公司章程>的议案》，鉴于 公司股票已被深圳证券交易所作出终止上市决定，根据《中华人民共和国公司法》 （以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、 《非上市公众公司监督管理办法》、《非上市公众公司监管指引第3号-章程必备 条款》和其他有关规定，为规范公司运营，确保公司经营的合规性、有效性，结 合公司实际情况，拟对《公司章程》部分条款进行修订，主要修订条款如下： | 修订前《公司章程》条文 | 修订后《公司章程》条文 | | --- | --- | | | 第一条 为维护广东太安堂药业股份有 | | | 限公司(以下简称"公司")、股东、职工和 | | 第一条 为维护广东太安堂药业股份有 | | | 限公司(以下简称"公司")、股东和债权人 | 债权人的合法权益，规范公司的组织和行为， | | | 根据《中华人民共和国公司法》(以下简称《公 | | 的合法权益，规范公司的组织和行为，根据 | | | 《中华人民共和 ...

股票代码：002433 股票简称：*ST 太安 公告编号：2024-045 广东太安堂药业股份有限公司 关于公司股票进入退市整理期交易首日的风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 二、公司股票退市整理期交易起始日及交易期限 特别提示： 1.公司股票于退市整理期届满的次一交易日摘牌，公司股票终止上市。 2.公司股票进入退市整理期的起始日为2024年6月14日，退市整理期为十五 个交易日，预计最后交易日期为2024年7月4日。 3.请投资者、证券公司等市场主体在股票摘牌前及时了结股票质押式回购、 约定购回、融资融券、转融通、深股通等业务。 4.对于将在股票摘牌后至完成退市板块初始登记期间到期的司法冻结业务， 建议有权机关在股票摘牌前通过原协助执行渠道提前办理续冻手续。 广东太安堂药业股份股份有限公司（以下简称"公司"）于2024年6月5日收 到深圳证券交易所（以下简称"深交所"）下发的《关于广东太安堂药业股份有 限公司股票终止上市的决定》（深证上2024【435】号），深交所决定终止公司 股票上市。根据《深圳证券交易所股票上市规则（2023年 ...

3.退市整理期间股票在风险警示板交易。退市整理期首个交易日，公司股票 价格无价格涨跌幅限制，此后每日涨跌幅限制为10%。 4.请投资者、证券公司等市场主体在股票摘牌前及时了结股票质押式回购、 约定购回、融资融券、转融通、深股通等业务。 5.对于将在股票摘牌后至完成退市板块初始登记期间到期的司法冻结业务， 建议有权机关在股票摘牌前通过原协助执行渠道提前办理续冻手续。 股票代码：002433 股票简称：*ST 太安 公告编号：2024-043 广东太安堂药业股份有限公司 关于收到股票终止上市决定的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1.终止上市的证券种类：人民币普通股，证券简称：*ST太安，证券代码： 002433。 2.公司股票于2024年6月14日复牌并进入退市整理期，退市整理期的交易期 限为十五个交易日，预计最后交易日期为2024年7月4日。 广东太安堂药业股份有限公司(以下简称"公司")于2024年6月5日收到深 圳证券交易所（以下简称"深交所"）下发的《关于广东太安堂药业股份有限公 司股票终止上市的决定》（深证上〔2024〕 ...

广东太安堂药业股份有限公司 关于公司股票进入退市整理期交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 股票代码：002433 股票简称：*ST 太安 公告编号：2024-044 特别提示： 1、广东太安堂药业股份有限公司（以下简称"公司"）股票于退市整理期 届满的次一交易日摘牌，公司股票终止上市。 2、公司股票进入退市整理期的起始日为2024年6月14日，预计最后交易日期 为2024年7月4日。 3、公司股票在退市整理期交易期间，公司将不筹划或实施重大资产重组事 项。 4、请投资者、证券公司等市场主体在股票摘牌前及时了结股票质押式回购、 约定购回、融资融券、转融通、深股通等业务。 5、对于将在股票摘牌后至完成退市板块初始登记期间到期的司法冻结业务， 建议有权机关在股票摘牌前通过原协助执行渠道提前办理续冻手续。 公司于2024年6月5日收到深圳证券交易所（以下简称"深交所"）下发的《关 于广东太安堂药业股份有限公司股票终止上市的决定》（深证上2024【435】号）， 深交所决定终止公司股票上市。根据《深圳证券交易所股票上市规则（2023年8 月修订） ...

关于广东太安堂药业股份有限公司股票终止上市的公告 根据本所《股票上市规则（2023年8月修订）》第9.3.14条的规定以及本所上市审核委员会的审议意 见，本所决定公司股票终止上市。公司股票自2024年6月14日起进入退市整理期交易，退市整理期届满 的次一交易日，本所对公司股票予以摘牌。 本所要求公司严格按照相关规定，做好退市整理期以及股票终止上市后续有关工作。 时间：2024-06-05 字体： 大 中 小 深圳证券交易所 2024年6月5日 广东太安堂药业股份有限公司（以下简称"公司"）2022年度财务会计报告被会计师事务所出具无法 表示意见的审计报告，公司股票交易自2023年5月5日起被实施退市风险警示。 2024年4月30日，公司披露的2023年年度报告显示，公司2023年年度财务会计报告被出具无法表示 意见的审计报告，触及本所《股票上市规则（2023年8月修订）》第9.3.11条第一款第三项规定的股票终 止上市情形。 ...

北 京 上 海 深 圳 杭 州 广 州 昆 明 天 津 成 都 宁 波 福 州 西 安 南 京 南 宁 济 南 重 庆 苏 州 长 沙 太 原 武 汉 贵 阳 乌鲁木齐 郑 州 石 家 庄 合 肥 海 南 青 岛 南 昌 大 连 银 川 • 拉 孜 • 香 港 巴 黎 马 德 里 斯 德 哥 尔 摩 纽 约 广州市天河区珠江东路 28 号越秀金融大厦 38 楼 邮编：510623 电话：(+86)(20) 3879 9345 传真：(+86)(20) 3879 9345-200 (二)本次股东大会的召开 国浩律师(广州)事务所 关于广东太安堂药业股份有限公司 2023 年年度股东大会的法律意见 广东太安堂药业股份有限公司： 根据中国证券监督管理委员会发布的《上市公司股东大会规则》(以下简称 《股东大会规则》)的要求，国浩律师(广州)事务所(以下简称"本所")接受广 东太安堂药业股份有限公司(以下简称"太安堂")的委托，指派郭佳、杨雪莹律 师(以下简称"本所律师")出席太安堂 2023 年年度股东大会(以下简称"本次股 东大会")，对本次股东大会的召集与召开程序、出席会议人员与召集人的资格、 表决程序与表决结果 ...

股票代码：002433 股票简称：*ST 太安 公告编号：2024-042 2、本次股东大会不涉及变更前次股东大会决议。 一、会议召开情况 1、会议召开时间 广东太安堂药业股份有限公司 2023年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无否决提案的情形。 现场会议时间：2024 年 5 月 20 日下午 14:50。 网络投票时间：2024 年 5 月 20 日。通过深圳证券交易所交易系统进行网络 投票的具体时间为：2024 年 5 月 20 日 9:15－9:25，9:30－11:30，13:00－15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为 2024 年 5 月 20 日 9:15 －15:00 的任意时间。 2、现场会议召开地点：汕头市金园工业区揭阳路28号广东太安堂药业股份 有限公司（以下简称"公司"或"太安堂"）麒麟园中座二楼会议室； 3、会议召开方式：现场投票和网络投票相结合方式； 4、会议召集人：公司董事会； 6、本次股东大会的召集、召开符合《公司法》、《上市公司股东大会 ...

股票代码：002433 股票简称：*ST 太安 公告编号：2024-041 广东太安堂药业股份有限公司 关于收到深圳证券交易所终止上市事先告知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、广东太安堂药业股份有限公司（以下简称"公司"）因公司2022年度财 务会计报告被出具无法表示意见的审计报告，公司股票交易自2023年5月5日起被 实施退市风险警示。 2024年4月30日，你公司披露相关公告显示，你公司股票交易被实施退市风 险警示后的首个年度财务会计报告被出具无法表示意见的审计报告。 你公司触及本所《股票上市规则（2023年8月修订）》第9.3.11条第一款第 三项规定的股票终止上市情形，本所拟决定终止你公司股票上市交易。 请你公司于2024年5月10日前向本所发回附件《送达回执》。根据本所《股 票上市规则（2023年8月修订）》《自律监管听证程序细则（2023年修订》等的 相关规定，你公司有权申请听证。如申请听证，你公司应当在收到本告知书之日 起五个交易日内，以书面形式向本所提出申请，并载明具体事项及理由。你公司 还可以在收到本告 ...

Financial Performance - The company's revenue for Q1 2024 was ¥68,608,687.70, a decrease of 50.75% compared to ¥139,317,832.02 in the same period last year[5] - The net loss attributable to shareholders was ¥54,811,763.46, an improvement of 10.79% from a loss of ¥61,443,810.03 in the previous year[5] - The company's basic and diluted earnings per share were both -¥0.07, an improvement of 12.50% from -¥0.08 in the same period last year[5] - Net loss for Q1 2024 was ¥56,703,754.46, compared to a net loss of ¥62,509,752.43 in Q1 2023, representing an improvement of 9.5%[28] - The company reported a total comprehensive loss of CNY 56,711,229.54 for Q1 2024, compared to a loss of CNY 62,759,313.15 in the previous year[29] Cash Flow - The net cash flow from operating activities was ¥50,340,238.24, a significant increase of 226.69% compared to -¥39,735,469.21 in the same period last year[5] - Net cash flow from operating activities increased by ¥90,075,707.45, a growth of 226.69%, primarily due to an increase in receivables and a decrease in procurement and payments[15] - The net increase in cash and cash equivalents was ¥50,599,955.32, a growth of 6209.50%, attributed to reduced net outflow from financing activities and increased net cash flow from operating activities[17] - Cash inflow from investment activities decreased by ¥73,071,282.90, a decline of 99.57%, mainly due to higher cash recovery from the disposal of fixed assets in the previous period[15] - Cash outflow from financing activities decreased by ¥199,833,539.93, a decline of 100.00%, as there were no repayments of borrowings and interest in the current period[16] - Cash outflows from financing activities totaled CNY 199,833,539.93, with no cash inflows reported for this period[31] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,284,118,286.75, a decrease of 1.78% from ¥3,343,704,279.05 at the end of the previous year[5] - Total liabilities decreased to ¥2,943,586,244.01 from ¥2,947,981,020.64, a decline of 0.1%[25] - The company's cash and cash equivalents decreased to ¥93,591,312.01 from ¥122,799,710.22, a decline of 23.8%[24] - Accounts receivable increased to ¥156,125,758.18 from ¥146,086,942.37, reflecting a rise of 6.9%[24] - Inventory levels rose slightly to ¥518,443,693.84 from ¥509,729,559.03, an increase of 1.4%[24] Operating Performance - Operating income decreased by ¥70,709,144.32, a decline of 50.75%, primarily due to heavy debt and insufficient working capital[10] - Operating costs decreased by ¥57,920,015.97, a decline of 50.15%, attributed to the drop in sales revenue[10] - Total operating revenue for Q1 2024 was ¥68,608,687.70, a decrease of 50.8% compared to ¥139,317,832.02 in the same period last year[27] - Total operating costs for Q1 2024 were ¥139,469,389.04, down 38.2% from ¥225,506,907.16 year-over-year[27] - The company reported a significant reduction in sales expenses to ¥14,768,915.21 from ¥25,813,024.60, a decrease of 42.7%[28] Research and Development - The company reported a decrease in research and development expenses by ¥881,374.71, a decline of 43.74%, due to insufficient funds[10] - Research and development expenses were reduced to ¥1,133,551.82 from ¥2,014,926.53, a decrease of 43.7%[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 46,801[19] - The largest shareholder, Taiantang Group Co., Ltd., holds 14.90% of the shares, totaling 114,261,032 shares[19] Legal and Regulatory - The company has received a court decision to terminate its pre-restructuring process, indicating ongoing financial challenges[20] - The first quarter report was not audited[32] - The company is set to implement new accounting standards starting in 2024[32]

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion yuan, representing a year-on-year growth of 15%[3]. - The company's operating revenue for 2023 was ¥410,361,348.39, a decrease of 36.43% compared to ¥645,534,178.29 in 2022[26]. - The net profit attributable to shareholders for 2023 was a loss of ¥2,210,086,620.5, representing a decline of 128.28% from ¥822,822,306 in 2022[26]. - The total assets at the end of 2023 were ¥3,343,704,279.05, down 42.11% from ¥6,562,516,043.50 at the end of 2022[26]. - The company's basic earnings per share for 2023 was -¥2.88, a decline of 128.57% from -¥1.07 in 2022[26]. - The company's total revenue for 2023 was approximately ¥410.36 million, a decrease of 36.43% compared to ¥645.53 million in 2022[64]. - The pharmaceutical segment contributed ¥395.20 million, accounting for 96.31% of total revenue, with a year-on-year decline of 37.22%[64]. - The revenue from proprietary Chinese medicine manufacturing was ¥172.36 million, representing 42.00% of total revenue, down 47.86% from ¥330.54 million in 2022[64]. - The company reported a gross margin of 14.33% for the pharmaceutical segment, a decrease of 66.16% year-on-year[66]. - The company reported a significant asset impairment provision at year-end, contributing to substantial losses in the fourth quarter[32]. Market Outlook and Strategy - The company has outlined a positive outlook for 2024, projecting a revenue growth of 10% to 12% based on market expansion strategies[5]. - The company is focusing on market expansion, targeting a 30% increase in distribution channels across tier-2 and tier-3 cities[5]. - A strategic acquisition of a local competitor is anticipated to enhance market share by 5% in the next fiscal year[5]. - The company plans to invest 100 million yuan in R&D for new technologies aimed at improving production efficiency[5]. - The company is focusing on three major product areas: dermatology, cardiovascular diseases, and reproductive health, through independent research and acquisitions[57]. - The company aims to become a leading enterprise in reproductive health, focusing on three major product series: dermatological, cardiovascular, and reproductive health drugs[99]. - The company plans to enhance its R&D and marketing efforts in traditional Chinese medicine, particularly in reproductive health products, while reducing debt and financial leverage risks[100]. Research and Development - The company continues to invest in product research and development, focusing on classic formulations and new drug development, including clinical trials for Qilin Wan[40]. - The company is conducting research on ancient classic prescriptions for new drug development, aiming to submit applications for new drug approvals[78]. - The company has implemented smart automation in its manufacturing processes, enhancing production capacity through 72 fully automated production lines[60]. - The company is actively engaged in the research and development of new products, with an investment of 800 million allocated for innovation initiatives[127]. - The company is increasing its R&D investment, collaborating with key universities and research institutions to develop new drug formulations and improve existing products[102]. Operational Challenges - The company is undergoing bankruptcy reorganization, which has led to a comprehensive review of its assets and liabilities[27]. - The company has faced uncertainties regarding its ability to continue as a going concern, as indicated in the recent audit report[27]. - The company is under pressure for short-term debt repayment due to bond issuance and bank loans, with ongoing efforts to reduce interest-bearing debt by focusing on core traditional products and new product innovation[109]. - The company is currently facing operational difficulties due to a significant decline in revenue and substantial debt repayment risks[157]. - The company has faced continuous losses for two consecutive years and is at risk of further revenue decline and substantial debt repayment challenges in the next year[179]. Governance and Compliance - The company maintains a strict governance structure in compliance with relevant laws, ensuring independent operations from its controlling shareholder[113]. - The company has established a performance evaluation and incentive mechanism for its management, linking compensation directly to operational performance[115]. - The company has a clear separation of assets and operations from its controlling shareholder, ensuring no competition in the same industry[118]. - The company has established an independent financial management system and internal audit department, ensuring no assets are occupied by shareholders or related parties[120]. - The company has implemented internal control measures to enhance operational efficiency and compliance[139]. Financial Management - The company reported a significant internal control deficiency related to fund management, which could lead to the inability to prevent or detect financial reporting errors[152]. - The company has committed to enhancing its expense management processes to ensure accurate recognition of market expenses[183]. - The company has established a comprehensive internal control system to improve operational standards and risk management[183]. - The company reported a total adjustment in other receivables of CNY 130,220,357.68, leading to a revised total of CNY 431,864,450.47[190]. - The company aims to complete the rectification of identified deficiencies by June 2024[152]. Social Responsibility and Sustainability - The company emphasizes environmental protection and energy conservation, aligning with national environmental requirements[41]. - The company has not faced any environmental penalties during the reporting period and does not belong to key pollutant discharge units[160]. - The company has consistently increased tax contributions to local and national governments, reflecting its commitment to social responsibility[168]. - The company is committed to sustainability initiatives, aiming to reduce carbon emissions by 30% over the next five years[128]. Shareholder Engagement - The participation rate in the first temporary shareholders' meeting of 2023 was 24.44%, held on January 19, 2023[122]. - The second temporary shareholders' meeting of 2023 had a participation rate of 27.76%, held on February 6, 2023[122]. - The annual shareholders' meeting for 2022 saw a participation rate of 23.94%, conducted on May 19, 2023[122]. - The company has not engaged in any investor communication activities during the reporting period[110].